Fig. 3

Bioactivity of TRAb in GD patients treated with ¹³¹I therapy. TRAb bioactivity was measured in 22 onset Graves’ disease patients without radioiodine therapy and 84 Graves’ disease patients treated with radioiodine therapy (1–6 months group [n = 20], 7–12 months group [n = 19], 13–60 months group [n = 29], >60 months group [n = 16]). A and B Show TSAb and TBAb activities in these patients, respectively. The gray circle represents patients with normal levels of TSAb and TBAb; the yellow circle represents patients with high TSAb; the red circle represents patients with high TBAb; the blue circle represents patients with high TSAb and TBAb simultaneously